Kenneth ThomasJohnsonMD

General Surgery • Hartford, CT

Physician

Join to view full profile

Dr. Johnson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Johnson's full profile

Already have an account?

Office
151 Farmington Ave
Hartford, CT 06156
Phone+1 860-636-9073
Is this information wrong?

Education & Training

University of ConnecticutResidency, Surgery, 1975 - 1976
University of ConnecticutResidency, Surgery, 1973 - 1975
Rutgers New Jersey Medical SchoolClass of 1974
The Hospital of Central ConnecticutInternship, Transitional Year, 1971 - 1972

Certifications & Licensure

CT State Medical License 1976 - 2024
NY State Medical License 1972 - 2011
MA State Medical License 1995 - 2010

Publications & Presentations

PubMed

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Bell, C., Graham, J., Earnshaw, S., Oleen-Burkey, M., Castelli-Haley, J., Johnson, K.> ;J Manag Care Pharm. 2007 Apr
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D.> ;Ann Neurol. 2007 Jan
Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw, S. R., Graham, J., Oleen-Burkey, M., Castelli-Haley, J., Johnson, K.> ;Appl Health Econ Health Policy. 2009 Sep 08
Glatiramer acetate therapy for multiple sclerosis: a review.
Perumal, J., Filippi, M., Ford, C., Johnson, K., Lisak, R., Metz, L., Tselis, A., Tullman, M., Khan, O.> ;Expert Opin Drug Metab Toxicol. 2006 Dec
Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
Castelli-Haley, J., Oleen-Burkey, M. A., Lage, M. J., Johnson, K.> ;J Med Econ. 2010
Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela, R. M., Costello, K., Chen, M., Said, A., Johnson, K. P., Dhib-Jalbut, S.> ;Mult Scler. 2007 Jul
Join now to see all